It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Millions more senior citizens and lower-income Americans could obtain coverage for costly anti-obesity drugs under a proposal ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...